SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Director Nostrand Robert L. Van Buys 10,000 Shares

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) Director Nostrand Robert L. Van acquired 10,000 shares of the business's stock in a transaction dated Thursday, June 12th. The shares were acquired at an average cost of $1.48 per share, with a total value of $14,800.00. Following the transaction, the director now owns 20,400 shares in the company, valued at approximately $30,192. This trade represents a 96.15% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

SELLAS Life Sciences Group Trading Up 0.6%

SELLAS Life Sciences Group stock traded up $0.01 during mid-day trading on Friday, hitting $1.66. The stock had a trading volume of 2,612,222 shares, compared to its average volume of 1,599,679. The firm has a market capitalization of $165.63 million, a P/E ratio of -2.41 and a beta of 2.25. The firm's 50 day moving average is $1.53 and its 200 day moving average is $1.27. SELLAS Life Sciences Group, Inc. has a one year low of $0.77 and a one year high of $2.12.

SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) last issued its earnings results on Tuesday, May 13th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.04. As a group, equities research analysts forecast that SELLAS Life Sciences Group, Inc. will post -0.57 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Opus Capital Group LLC boosted its holdings in SELLAS Life Sciences Group by 5.5% in the 4th quarter. Opus Capital Group LLC now owns 238,500 shares of the company's stock worth $248,000 after buying an additional 12,400 shares during the period. Virtu Financial LLC lifted its stake in SELLAS Life Sciences Group by 30.9% in the 1st quarter. Virtu Financial LLC now owns 53,861 shares of the company's stock worth $58,000 after purchasing an additional 12,706 shares in the last quarter. Northern Trust Corp lifted its stake in SELLAS Life Sciences Group by 33.6% in the 4th quarter. Northern Trust Corp now owns 134,721 shares of the company's stock worth $140,000 after purchasing an additional 33,878 shares in the last quarter. Geode Capital Management LLC lifted its stake in SELLAS Life Sciences Group by 21.2% in the 4th quarter. Geode Capital Management LLC now owns 733,546 shares of the company's stock worth $763,000 after purchasing an additional 128,355 shares in the last quarter. Finally, Anson Funds Management LP lifted its stake in SELLAS Life Sciences Group by 50.2% in the 4th quarter. Anson Funds Management LP now owns 1,192,266 shares of the company's stock worth $1,240,000 after purchasing an additional 398,431 shares in the last quarter. Institutional investors own 17.38% of the company's stock.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.